Results per Page:
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection
A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.
HVTN at the 24th International AIDS Conference in Montreal
HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more